Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 5/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455509 | 0.72 | ELANE (0.47) | GAAL3MBTL1ELANECTSGPRTN3 | |
| SCHEMBL4482450 | 0.69 | L3MBTL1 (0.45) | GAAL3MBTL1ELANECTSGPRTN3 | |
| SCHEMBL16174713 | 0.61 | ELANE (0.44) | GAAL3MBTL1ELANECTSGPRTN3 | |
| SCHEMBL16174913 | 0.60 | ELANE (0.51) | GAAL3MBTL1ELANECTSGPRTN3 | |
| SCHEMBL6810670 | 0.60 | ELANE (0.43) | GAAL3MBTL1ELANECTSGPRTN3 | |
| SCHEMBL8105297 | 0.59 | TP53 (0.41) | ELANETP53 | |
| SCHEMBL19809144 | 0.59 | OPRL1 (0.40) | ELANEKMT2ATP53 | |
| SCHEMBL3318278 | 0.59 | PIK3CD (0.51) | GAAL3MBTL1ELANECTSGPRTN3 | |
| SCHEMBL11256566 | 0.59 | ELANE (0.42) | ELANECTSGPRTN3CAPN1ALDH1A1 | |
| SCHEMBL18805033 | 0.59 | ELANE (0.42) | GAAL3MBTL1ELANECTSGPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GAA 121/4885L3MBTL1 4751/4885ELANE 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.